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AbstrACt
Objective Evaluate the feasibility and acceptability 
of routine aspirin in low-risk women, compared with 
screening-test indicated aspirin for the prevention of pre-
eclampsia and fetal growth restriction.
Design Multicentre open-label feasibility randomised 
controlled trial.
setting Two tertiary maternity hospitals in Dublin, Ireland.
Participants 546 low-risk nulliparous women completed 
the study.
Interventions Women underwent computerised 
randomisation to: Group 1—routine aspirin 75 mg from 
11 until 36 weeks; Group 2—no aspirin and; Group 3—
aspirin based on the Fetal Medicine Foundation screening 
test.
Primary and secondary outcome measures (1) 
Proportion agreeing to participate; (2) compliance with 
protocol; (3) proportion where first trimester uterine 
artery Doppler was obtainable and; (4) time taken to 
issue a screening result. Secondary outcomes included 
rates of pre-eclampsia and small-for-gestational-age 
fetuses.
results 546 were included in the routine aspirin (n=179), 
no aspirin (n=183) and screen and treat (n=184) groups. 
546 of 1054 were approached (51.8%) and enrolled. 
Average aspirin adherence was 90%. The uterine artery 
Doppler was obtained in 98.4% (181/184) and the average 
time to obtain a screening result was 7.6 (0–26) days. Of 
those taking aspirin, vaginal spotting was greater; n=29 
(15.1%), non-aspirin n=28 (7.9%), OR 2.1 (95% CI 1.2 to 
3.6). Postpartum haemorrhage >500 mL was also greater; 
aspirin n=26 (13.5%), no aspirin n=20 (5.6%), OR 2.6 
(95% CI 1.4 to 4.8).
Conclusion Low-risk nulliparous women are open 
to taking aspirin in pregnancy and had high levels of 
adherence. Aspirin use was associated with greater rates 
of vaginal bleeding. An appropriately powered randomised 
controlled trial is now required to address the efficacy and 
safety of universal low-dose aspirin in low-risk pregnancy 
compared with a screening approach.
trial registration number ISRCTN (15191778); Post-
results.
IntrODuCtIOn 
Low-dose aspirin use prior to 16 weeks gesta-
tion can reduce the incidence of pre-ec-
lampsia in at-risk pregnancies. When given at 
this stage, at a dose of 75 mg, the efficacy in 
low-risk pregnancies is unknown.1 2 With the 
emergence of first trimester screening tests for 
pre-eclampsia such as that of the Fetal Medi-
cine Foundation (FMF), one can predict from 
11 weeks', the risk of pre-eclampsia.3 Inter-
nationally, there are conflicting consensus 
statements on screening methods and which 
women meet criteria for aspirin use.4 Appli-
cation of the FMF screening test and provi-
sion of low-dose aspirin to screen positive 
women can significantly reduce the incidence 
of early-onset pre-eclampsia (4.3% aspirin vs 
1.6% placebo, p=0.004), although predictive 
performance of the algorithm appears to vary 
between populations.5 It has been proposed 
that performance of the FMF algorithm is 
superior to the methods recommended by 
the National Institute for Health and Care 
strengths and limitations of this study
 ► Robust multicentre randomised controlled trial 
design.
 ► Three methods were used to assess aspirin 
adherence.
 ► Standardisation of methods.
 ► Potential introduction of reporting bias through 
open-label design.
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Excellence (NICE) and American College of Obstetri-
cians and Gynecologists.6 It may be more efficacious to 
prescribe low-dose aspirin universally, although there is 
no evidence to support such a policy as yet.7 To determine 
this, one must first evaluate if low-risk women are willing 
to take aspirin in pregnancy and if undergoing a compre-
hensive screening test is realistic in a routine setting. 
Hence, the primary objective of this multicentre open-
label feasibility randomised controlled trial (RCT) was to 
evaluate the acceptability and feasibility of women taking 
aspirin 75 mg from beyond 11 weeks’ gestation versus 
screening-test indicated aspirin. Secondary outcomes 
included rates of: (1) pre-eclampsia; (2) small-for-gesta-
tional-age (SGA) infants; (3) preterm delivery; (4) admis-
sion to neonatal intensive care; (5) placental abruption; 
(6) any reported death and; (7) acceptability of women 
taking aspirin routinely versus test-indicated aspirin, 
assessed by a questionnaire.
MethODs
study design
This open-label feasibility multicentre RCT was 
performed in two Irish tertiary maternity hospitals with 
18 000 deliveries per annum collectively. The aim was 
to include three centres; however, there was a delay in 
the local ethics committee decision for the third centre 
(subsequently approved), which was excluded in the 
interests of study schedule. The protocol for this multi-
centre RCT has been published8 and was prospectively 
authorised by the Health Products Regulatory Authority 
and National Maternity Hospital Central Ethics 
Committee. The trial was supported by Perinatal Ireland 
Health Research Board (HRB) and the HRB Mother and 
Baby Clinical Trials Network following external peer-re-
view for scientific quality. The funder of the study had no 
role in study design, data collection, data analysis, data 
interpretation or writing of the manuscript. An inde-
pendent Trial Steering Committee and Data Monitoring 
Committee met quarterly to oversee the safety of the trial 
participants.
Nulliparous women over 18 years old between 11 and 
13+6 weeks’ gestation with a viable singleton pregnancy 
who did not meet criteria for taking aspirin based upon 
major pre-eclampsia risk-factors (chronic kidney disease; 
autoimmune disease, eg, systemic lupus erythematosus, 
diabetes mellitus and chronic hypertension) were eligible 
for inclusion and thus were recruited at antenatal booking 
clinics selected at random.9 In Ireland, it is currently 
not routine obstetric practice to recommend aspirin in 
women who do not have an aforementioned major risk 
factor for pre-eclampsia as defined by NICE.9 Exclusion 
criteria included participants already taking part in a 
clinical trial, co-existence of a fetal congenital anomaly 
at recruitment or those with aspirin hypersensitivity. All 
participants provided written informed consent and were 
recruited by the research clinician at the first trimester 
antenatal booking visit.
randomisation
Participants underwent enrolment and online computer-
ised randomisation by the study sonographer or clinician 
based on blocks of six to: Group 1—aspirin 75 mg from 
11 to 13+6 weeks' once daily until 36 weeks’ gestation; 
Group 2—no aspirin and; Group 3—aspirin depending 
on the result of the FMF screening test. Subjects in 
non-aspirin taking groups underwent routine antenatal 
care. The randomisation sequence was determined prior 
to study commencement by the off-site statistician and 
was concealed from assessors, with both the assessor and 
participant seeing the group allocation at the same time, 
following online selection.
Intervention
Enteric-coated Nu-Seals Aspirin (acetylsalicylic acid) 
75 mg orally once daily at night from 11 to 36 weeks’ gesta-
tion was provided free of charge from Alliance Pharma, 
which were independent of study protocol and analysis. 
A dose of 75 mg was used as this is currently the standard 
recommended dosage in the UK and Ireland for at-risk 
women.9
Aspirin adherence was assessed subjectively via 
patient-reported diary cards and tablet counts (checked 
by both the research clinician and pharmacist) and 
objectively by assessment of change in urinary 11-dehy-
droxo-thromboxane-B2 (TxB2). Any reduction in TxB2 
between first (pre-aspirin) and second trimester (post-as-
pirin) levels was taken to suggest that a subject had 
ingested aspirin within the last 10 days.10
baseline review and follow-up
Participants underwent two scheduled study visits, at 
study recruitment and again at 20–22 weeks' (to coin-
cide with their fetal anatomy scan which was performed 
at the same time) with diary cards and aspirin tablets 
returned to the research team at 36 weeks’ gestation. 
Participants completed an anonymous questionnaire at 
20–22 weeks based on acceptability of taking aspirin in 
pregnancy.
Study assessments at the time of the recruitment visit 
included the FMF screening test, the results of which 
were assessed for those in Group 3 (screen positive and 
received aspirin (3A) and screen negative no aspirin 
(3B)). The FMF screening test was not routine prac-
tice within Ireland. Components of the screening test 
included: maternal history (including ovulation-in-
duced conception, race, body mass index, age, mother 
with pre-eclampsia); mean arterial blood pressure 
(MAP); uterine artery Doppler pulsatility index and; 
pregnancy-associated plasma protein-A (PAPP-A) and 
placental-like growth factor (PLGF) multiples of the 
median. To determine the risk of pre-eclampsia, the 
FMF algorithm was used and based on a screen posi-
tive rate of 5%, a cut-off for pre-eclampsia prior to 
42 weeks at greater than 1:8 was used.3 This cut-off 
was selected with the aim of capturing the majority 
of pre-eclamptics; both preterm and post-term and at 
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the time of study commencement, this was the optimal 
screening algorithm for the detection of any pre-ec-
lampsia. Two non-blinded trained clinical research 
sonographers acquired the first trimester uterine artery 
Doppler waveforms and MAP and interpreted the find-
ings. MAP was assessed using an automated blood pres-
sure monitoring device as outlined by the technique 
stipulated by the FMF.11 Uterine artery Doppler veloci-
metry was acquired using Viewpoint Version 5.6.16 GE 
Healthcare, 2012 and Voluson Expert 730, GE 2012 
using the technique outlined by the International 
Society of Ultrasound in Obstetrics and Gynecology. 
The pulsatility index was measured from both uterine 
arteries and an average value was calculated.12
A maternal blood sample was analysed for PAPP-A and 
PLGF under standard conditions using a 6000 DELFIA 
Xpress, PerkinElmer, 2014 clinical random access 
screening platform in the hospital clinical biochem-
istry laboratory. A quantitative immunoturbimetric 
TxBCardio immunoassay was used to determine TxB2 
levels in urine samples obtained via both study visits. 
These were then standardised as a ratio with creatinine 
levels and expressed as pg/mg creatinine.
Outcomes
The primary objective of this study was to evaluate 
the feasibility and acceptability of low-risk nulliparous 
women taking aspirin versus test-indicated aspirin in 
pregnancy. Outcome measures included:
1. The proportion of eligible women agreeing to partic-
ipate in a trial where aspirin is prescribed routinely 
(feasibility).
2.  Compliance with study protocol, as measured by the 
following: (1) adherence to aspirin (acceptability), (2) 
attendance at study visits (acceptability), (3) satisfacto-
ry collection of all endpoints and variables (feasibility), 
(4) specific study protocol violations (feasibility).
3. The proportion of women in whom it was possible to 
obtain first trimester transabdominal uterine artery 
Doppler velocimetry examination (feasibility).
4. Proportion of women with a completed screening test 
who were issued the screening result within 1 week of 
having the test performed (feasibility).
Secondary outcomes included rates of: (1) pre-ec-
lampsia; (2) SGA infants (customised sex-specific 
birth weight <10th centile); (3) preterm delivery prior 
to 34 weeks; (4) admission to the neonatal intensive 
care unit (NICU); (5) placental abruption; (6) any 
reported death (stillbirth, neonatal or infant death) 
and (7) acceptability of women taking aspirin routinely 
versus test-indicated aspirin as assessed by an anony-
mous questionnaire at 20–22 weeks. As part of routine 
antenatal care, women had an appointment with their 
midwife and/or clinician at booking (11–14 weeks'), 
16 weeks', 18–20 weeks', 25 weeks', 28 weeks', 31 weeks', 
34 weeks', 36 weeks', 38 weeks', 40 weeks' and 41 weeks' 
of gestation in line with hospital protocol. During 
each visit, blood pressure was assessed using mercury 
sphygmomanometry and a urine dipstick for protein-
uria was performed with symphysis-fundal height and 
or fetal biometrical ultrasound assessment as appro-
priate. Pre-eclampsia was defined based on the defi-
nition from the International Society for the Study of 
Hypertension in Pregnancy, with new-onset hyperten-
sion (>140 mm Hg systolic or >90 mm Hg diastolic) 
after 20 weeks’ gestation associated with: (1) protein-
uria of at least 1 g/L (2+) on urine dipstick testing, 
(2) maternal organ dysfunction and/or (3) fetal 
growth restriction (FGR).13 Suspicion of a diagnosis of 
pre-eclampsia at an antenatal visit prompted further 
investigation in the fetal assessment unit with clinical 
examination, blood testing (urea and creatinine, liver 
function tests and full blood picture), 24-hour urine 
collection for proteinuria and departmental fetal 
ultrasound assessment with final diagnosis made by an 
obstetrician.
Safety data were reported as adverse and serious 
adverse events and participants that discontinued from 
the study were recorded in addition to the reason for 
discontinuation and outcome. As an assessment of 
postpartum haemorrhage, blood loss was weighed at 
the time of delivery.
statistical analysis
As outlined in the published study protocol, the projected 
sample size for this study was 500 women across two sites 
with 18 000 deliveries per annum collectively.8 To deter-
mine pre-eclampsia as a primary outcome, the antici-
pated number of patients required is over 15 000 women. 
As this study aimed to determine the feasibility of such 
a study, 500 participants were more than adequate as 
3% of the number required for a substantive study is 
required (n=450).14 Accounting for a dropout rate of 
10% (n=45), 500 participants were adequate to obtain 
the primary outcome. Analysis was performed by a stat-
istician using SAS v.20 on the intention-to-treat (ITT) 
population, which included all participants randomised, 
who had completed the full second trimester assessment. 
Measures of variance included SD. Follow-up of serious 
adverse events continued until 28-days following delivery. 
Adverse events were reported as odds ratios (ORs) and 
uncertainty was expressed using 95% CIs. No hypothesis 
tests were performed.
Patient involvement
Although patients were not directly involved in devising 
the study protocol and design, the burden of the RCT 
intervention (ie, taking aspirin and undergoing the 
FMF screening test) was assessed by means of an anon-
ymous questionnaire completed at 20–22 weeks’ gesta-
tion. At the time of study participation, subjects were 
informed that study results could be viewed following 
publication on the study website http:// perinatalire-
land. ie/ research/ test/
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results
Subjects were recruited between the 8 May 2014 and 23 
September 2015 with follow-up of participants until 11 
April 2016, when the study was ended by the steering 
committee following delivery of the final patient as 
the target sample size had been achieved. In total, 
1054 eligible women were approached to take part in 
the study and of these, 557 underwent randomisation 
(figure 1). In the screen and treat population (Group 
3) n=184, 13 (7.1%) women had a risk of developing 
pre-eclampsia >1:8 and subsequently started taking 
aspirin until 36 weeks’ gestation. Eleven women were 
excluded from the study leaving 546 in the ITT popula-
tion. In total, there were 192 women in the ITT group 
who were taking aspirin as per randomisation and 354 
not taking aspirin. Baseline characteristics were similar 
and the summaries are presented in table 1.
Primary outcomes
i. The proportion of eligible women agreeing to par-
ticipate in a trial where aspirin is prescribed routine-
ly (feasibility); 1054 women were approached who 
were eligible to partake. 497 were subsequently not 
enrolled as they did not want to take aspirin n=454 or 
for an alternative reason n=43, for example, appoint-
ment did not suit. Hence, 546/1054 (51.8%) wom-
en were willing to partake in a study where they may 
have to take aspirin routinely.
ii. Compliance with study protocol, as measured by the 
following: (A) adherence to aspirin (acceptability), 
(B) attendance at study visits (acceptability), (C) 
satisfactory collection of all endpoints and variables 
(feasibility), (D) specific study protocol violations 
(feasibility):
Figure 1 Consort diagram.
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A. Of those women included in the analysis who 
were taking aspirin (n=192), the average adher-
ence based on patient-reported diary cards was 
96.0% and based on tablet counts it was 95.0%. 
Seven women were non-adherent and 19 (9.9%) 
were poorly compliant (<80%). Average adher-
ence was 95.0% in both the test-indicated aspirin 
group (3A) and routine aspirin group (1) (ta-
ble 2). The median first trimester pre-aspirin urine 
TxB2 level was 8662.2 pg/mg (IQR 2014.5–9931.5) 
and second trimester (post-aspirin) 2285.1 pg/
mg (IQR 591.0–2300.1). The percentage change 
in TxB2 was then assessed for all paired samples 
(n=147) and found that 124/147 (84.4%) of sub-
jects had a fall in TxB2 levels between the first and 
second trimesters versus 23/147 (15.6%) who had 
an increase. The greater the reduction in urinary 
TxB2 pre-aspirin and post-aspirin dose, the greater 
the degree of aspirin adherence, as demonstrated 
in figure 2. Patient groups were similar (routine 
aspirin and screen-positive aspirin) in relation to 
adherence measures of tablet counts, diary cards 
and percentage change in urine TxB2.
B. Of those who underwent randomisation (n=557), 
11 were excluded prior to fulfilment of study par-
ticipation requirements (attendance at second 
study visit). Of the 11, three withdrew consent for 
participation as they decided that they did not 
wish to take aspirin following randomisation.
C. Of all 546 subjects, collection of outcome measures 
and variables were obtained for all apart from the 
questionnaire on patient acceptability, which was 
completed in 97.1% (530/546).
Table 1 Baseline characteristics of the study population
Characteristic
Low-dose aspirin,
n=179
No aspirin,
n=183
Screen and treat,
n=184
Age (years) 33 (19–44) 34 (18–43) 33 (19–44)
Race, n (%)
  White 181 (97.9) 179 (95.7) 180 (97.3)
  Black 1 (0.5) 2 (1.1) 0 (0)
  Asian 3 (1.6) 6 (3.2) 5 (2.7)
  Other 0 0 (0) 0 (0)
Completed secondary school, n (%) 136 (73.5) 143 (76.4) 152 (82.2)
BMI (kg/m2) 25.2 (17.4–39.4) 22.9 (17.7–41.4) 23.8 (18.1–45.2)
Gestational age (weeks) 12.9 (11.1–13.9) 12.9 (11.1–13.9) 12.9 (11.3–13.9)
Smoking,n (%) 17 (9.2) 11 (5.9) 7 (3.8)
Subject’s mother had pre-eclampsia,n (%) 7 (3.8) 10 (5.4) 10 (5.4)
Conception, n (%)
  IVF 5 (2.7) 9 (4.8) 8 (4.3)
  ICSI 3 (1.6) 4 (2.1) 3 (1.6) 
  Ovulation induction 5 (2.7) 6 (3.2) 6 (3.2)
  Spontaneous 172 (93.0) 168 (89.9) 170 (91.9)
Previous miscarriage, n (%) 20 (10.8) 31 (16.6) 31 (16.8)
Where n (%) is not expressed, average and range are demonstrated.
BMI, body mass index, ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilisation.
Table 2 Primary outcomes of feasibility and adherence
Adherence 
and feasibility 
parameter
Low-dose 
aspirin
(n=179)
No aspirin
(n=183)
Screen and 
treat
(n=184)
Ease of Doppler acquisition
  Very easy 8 (4%)
  Easy 53 (29%)
  Fair 61 (33%)
  Difficult 60 (32%)
  Unobtainable 3 (2%)
  Days to PLGF/
PAPP-A visit 1
7.6 (0–26)
  PLGF/PAPP-A 
result>16 weeks
5 (3%)
Time taken for visit 1 
(minutes)
60 (30–100) 60 (25–90) 60 (25–90)
Median adherence 
tablet counts
96% 95% (screen 
positive)
Median adherence 
diary cards
94% 95% (screen 
positive)
Non-adherent 7 (4%) 0 (0%)
PAPP-A, pregnancy-associated plasma protein-A; PLGF, 
placental-like growth factor.
 o
n
 7 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022056 on 28 July 2018. Downloaded from 
6 Mone F, et al. BMJ Open 2018;8:e022056. doi:10.1136/bmjopen-2018-022056
Open access 
D. Six protocol violations were recorded (0.01 per 
100 participants) including women transferring 
care to another hospital (n=3), incorrect randomi-
sation of women who did not meet inclusion cri-
teria (n=2) and a subject in the non-aspirin group 
who started taking aspirin on the advice of their 
clinician (n=1).
iii. The proportion of women in whom it was possible 
to obtain first trimester transabdominal uterine 
artery Doppler velocimetry (feasibility); the FMF 
screening test was completed in 98.4% (181/184) 
following successful uterine artery Doppler velocim-
etry acquisition, of which one was obtained vaginally 
due to challenges with abdominal acquisition, with 
an overall sonographer reported ease of acquisition 
3.1 (SD ±0.91) (score 1 (easy) to 5 (unobtainable)) 
(table 2).
iv. The proportion of women with a completed screen-
ing test issued the result within one week of the test 
(feasibility); the average time to obtain the laboratory 
analysed PAPP-A and PLGF results so that a screen-
ing result could be issued was 7.6 days (0–26) with 
78 (42.4%) of women waiting greater than one week 
and five women being beyond 16 weeks' prior to re-
sult availability (table 2).
secondary outcomes
There was no difference between groups in relation to 
secondary outcomes (online supplementary table S1). 
For the overall cohort, there were three cases of early-
onset pre-eclampsia <34 weeks (0.55%), n=22 (4.03%) 
any pre-eclampsia, n=57 (10.44%) SGA infants and 
15.02% (n=82) placental disease. Secondary outcomes for 
groups 3A (screen-positive aspirin) and 3B (screen-nega-
tive no aspirin) are demonstrated in online supplemen-
tary table S2. Despite taking aspirin, there remained 
a greater number with pre-eclampsia at <37 weeks in 
the screen-positive versus the screen-negative group, 
although numbers were small (n=2 (15.4%) vs n=2 
(1.2%)). In terms of taking aspirin in a subsequent preg-
nancy, the questionnaire revealed that 92.3% (489/530) 
were willing to take aspirin in a subsequent pregnancy; 
92.5% (173/187) of aspirin takers and 91.5% (314/343) 
of non-aspirin takers.
safety
The adverse event profile differed between groups but 
not the serious adverse event profile (table 3 and online 
supplementary table S3). There were six perinatal deaths, 
all of which underwent postmortem. In the aspirin group, 
there was one placental abruption and one case of inter-
villous haemorrhage. Perinatal deaths in the non-aspirin 
groups were due to delayed villous maturation, severe 
FGR, fetal thrombotic vasculopathy and neonatal septi-
cemia. There was an observable difference between 
groups in terms of reported vaginal spotting aspirin 15.1% 
versus non-aspirin 7.9% OR 2.1 (CI 1.2 to 3.6), which was 
not associated with pregnancy loss. Similarly, the rate of 
PPH >1000 mL was higher in the aspirin group. However, 
the numbers were small. Rates of blood transfusion or 
significant haemoglobin drop to <8 g/dL were similar.
DIsCussIOn
Main findings
This feasibility RCT has found that low-risk nulliparous 
women were open to taking aspirin in pregnancy and 
were adherent, with a willingness to take it again in a 
subsequent pregnancy. We can say this as, comparing 
findings to other RCTs in pregnancy, of which there 
are few, the uptake in this RCT was much higher, as was 
adherence (eg, Chiswick, et al 2015; 35% enrolment and 
65%–67% adherence with metformin use).15 This is the 
first trial of its kind, which has assessed the acceptability 
of women taking aspirin in low-risk pregnancy and the 
feasibility of an integrated screening test in a routine clin-
ical setting.
strengths and limitations
The strengths of this study are the multicentre RCT 
design with robust protocol and oversight and previ-
ously published methodology. Allocation bias was limited 
by the use of a prospective approach and selection bias 
was limited through randomisation. The fact that the 
same two sonographers and biochemists were respon-
sible for conducting the screening test with the use of 
quality control standards for test completion using the 
same equipment and technique for all subjects optimised 
reproducibility. There were a low number of dropouts 
and almost all patient outcomes were recorded. Although 
there is currently no validated scientific method of 
assessing aspirin adherence,16 a laboratory assessment 
of change in TxB2 served as a more objective measure, 
thus strengthening reliability. Study weaknesses were 
primarily that PAPP-A and PLGF analysis was performed 
Figure 2 Histogram demonstrating percentage change in 
urinary thromboxane-B2 levels pre-aspirin and post-aspirin 
administration (n=147) (TxB2=urinary thromboxane level).
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in the laboratory using validated methods with quality 
assurance, as opposed to the bedside point-of-care tests, 
hence it took longer to obtain a result. In a non-research 
setting with a greater throughput of patients, one could 
anticipate a faster turnaround time. Additionally. the 
open-label nature of the study meant that safety recording 
was open to reporting bias, and as is often the case with 
RCTs the uptake of subjects demonstrated dominance for 
Table 3 Adverse and serious adverse events in aspirin and non-aspirin taking groups
Event Aspirin, n=192 Non-aspirin, n=354 OR (95% CI)
Adverse events
  Adverse events, N 123 143 2.6 (1.8 to 3.8)
  Vaginal spotting, n (%) 29 (15.1) 28 (7.9) 2.1 (1.2 to 3.6)
  Postpartum haemorrhage, n (%)
   > 500 mL 26 (13.5) 20 (5.6) 2.6 (1.4 to 4.8)
   >1000 mL 7 (3.6) 5 (1.4) 2.8 (0.9 to 9.0)
   Blood transfusion 3 4 0.5 (0.1 to 2.7)
   Hb drop < 8 g/dL 4 7 0.3 (0.1 to 1.4)
Serious adverse event
  NICU admission
   Sepsis 3 2
   Hypoglycaemia 0 1
   Prematurity 1 4
   Jaundice 1 1
   Persistently low Apgar 1 3
   TTN 1 3
   Meconium aspiration 1 0
   Hypoxic ischaemic encephalopathy 1 1
   Very low birth weight 0 1
  Total 9 16 1.04 (0.45 to 2.40)
  Perinatal death 2 4
  Total 2 4 0.92 (0.17 to 5.10)
  Maternal admission
   Preterm labour 3 2
   Pre-eclampsia 8 7
   Antepartum haemorrhage 3 7
   PPROM 0 2
   Fetal compromise 1 2
   Infection 2 5
   Other 4 1
  Total 21 26 1.55 (0.85 to 2.83)
  Congenital anomaly
   Cardiac 1 2
   Gastrointestinal 3 2
   Neurological 0 1
   Renal 0 1
  Total 4 6 1.23 (0.34 to 4.43)
  Total serious adverse events 36 52 1.34 (0.84 to 2.14)
There may be >1 adverse event or serious adverse event per subject.
Very low birth weight ≤1500 g. 
Hb, haemoglobin; NICU, neonatal intensive care unit; PPROM, preterm premature rupture of membranes; TTN, transient tachypnoea of the 
newborn
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educated women. In RCTs, there is always a risk of intro-
ducing a Hawthorne effect, whereby subjects act differ-
ently in the confines of an RCT as to how they would in 
a real-life setting, hence adherence rates may have been 
over-represented.17 A third trimester visit may have added 
strength to the study to assess objectively for aspirin 
adherence and patient satisfaction; however, as adher-
ence prior to 16 weeks was deemed the critical time point 
for pre-eclampsia prevention, follow-up at 20–22 weeks 
was selected.
Interpretation
A recently published large RCT from the FMF found 
that, following application of FMF screening and subse-
quent randomisation of women deemed to be at risk of 
preterm pre-eclampsia to aspirin 150 mg versus placebo, 
there was a reduction in the incidence of preterm 
pre-eclampsia in the aspirin arm.5 Our study differs on 
several counts: (1) routine aspirin arm—use of a third 
arm assessing provision of routine aspirin assessed the 
acceptability and feasibility of this policy; (2) aspirin 
dosage (150 mg vs 75 mg)—in light of limited evidence 
on dosage and effect, the safest lowest effective dose was 
selected. A recent meta-analysis, published since comple-
tion of this study suggests that there is an aspirin dose–
response effect, with higher doses of aspirin taken prior 
to 16 weeks’ gestation, associated with a greater reduction 
in pre-eclampsia and FGR compared with standard lower 
doses.18 When supported by robust safety data when using 
higher dosing, this is something to consider in future 
studies and clinical practice; (3) adverse events—rates of 
PPH and vaginal bleeding were reported. This informa-
tion would be useful from the FMF study in light of the 
higher aspirin dosing regimen and; (4) our study was not 
powered to detect a difference in clinical outcome, with 
the primary focus being feasibility and acceptability.
Few studies have assessed the acceptability of non-routine 
medications in pregnancy. In the developing world, preg-
nant women are willing to take calcium, oral iron and micro-
nutrients.19–21 If instructed about potential side-effects and 
reminded frequently, women had higher levels of adher-
ence with the greatest barrier being forgetfulness. Average 
medication adherence in pregnancy for chronic illness is 
higher than for non-routine medications at 90%–95%,22 
hence it its promising that we have noted a rate as high 
as this in our own study. There was a slight discrepancy in 
adherence assessed via tablet counts and diary cards and 
that more objectively assessed via TxB2. Reasons for this may 
include the potential for aspirin resistance, which although 
not formally assessed in this study can be increased when 
using an enteric-coated preparation.23
The FMF screening test was feasible in terms of 
acquiring first trimester uterine artery Doppler velocim-
etry measurements, though delays were encountered in 
obtaining laboratory analysed PAPP-A and PLGF. This 
is relevant as it reflects the practical aspects of such a 
screening test in a clinical real-life setting. Improved 
protocols between the clinical and laboratory staff would 
be required to allow patients receive results within a 
reasonable timeline.
In terms of vaginal spotting and clinically significant 
PPH with aspirin use, the findings of this study are 
comparable with previous studies although evidence 
of increased antenatal and postnatal bleeding requires 
further investigation, most notably with the use of aspirin 
at doses greater than 75 mg.24 25 Due to the open-label 
nature of this study as opposed to placebo control, there 
is always a potential of reporting bias of bleeding in the 
aspirin arms. Although generally safe in pregnancy, it 
may be worthwhile considering cessation of aspirin at 
32–34 weeks’ gestation with the aim of reducing the 
risk of PPH, as opposed to 36 weeks' and of informing 
women of the unwanted side effect of increased vaginal 
spotting.
COnClusIOn
It has been proposed that the most cost-effective approach 
to reducing pre-eclampsia is the provision of an effective, 
affordable and safe intervention applied to all mothers 
without prior testing to assess levels of risk.7 An algo-
rithm-based screen-and-treat approach, as proposed by the 
FMF can reduce rates of preterm pre-eclampsia when doses 
of 150 mg of aspirin are used. This study was not powered to 
detect a difference in rates of pre-eclampsia between groups, 
yet has taken the first step to address if low-risk nulliparous 
women are open to taking aspirin in the first instance and 
if application of a screening algorithm is feasible. Moving 
forward, an RCT is now required to address the efficacy of 
universal low-dose aspirin in low-risk pregnancy compared 
with a screening-based approach. This will require signifi-
cant numbers due to the low incidence of early-onset pre-ec-
lampsia. Although women were open to taking aspirin in 
pregnancy compared with other RCTs involving medication, 
almost twice the number enrolled had to be approached 
to obtain adequate study participants. This must be consid-
ered when planning a future trial.
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